Grifols, S.A. (GRFS) News
Filter GRFS News Items
GRFS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GRFS News Highlights
- GRFS's 30 day story count now stands at 4.
- Over the past 20 days, the trend for GRFS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NGL, ZTS and DNN are the most mentioned tickers in articles about GRFS.
Latest GRFS News From Around the Web
Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.
GRFS or ZTS: Which Is the Better Value Stock Right Now?GRFS vs. ZTS: Which Stock Is the Better Value Option? |
Are You Looking for a Top Momentum Pick? Why Grifols (GRFS) is a Great ChoiceDoes Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
5 Best Breakout Stocks to Invest in for Attractive ReturnsGrifols (GRFS), Denison Mine Corp (DNN), NGL Energy Partners (NGL), Macatawa Bank (MCBC) and Navient (NAVI) have been selected as the breakout stocks for today. |
GRFS vs. ZTS: Which Stock Is the Better Value Option?GRFS vs. ZTS: Which Stock Is the Better Value Option? |
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsGrifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment. |
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin DeficiencyStudy designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenousThis first in-human subcutaneous approach to treating alpha1-antitrypsin deficiency, if proven successful in clinical trials, could give patients the convenience and flexibility to administer their medication from home BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, M |
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates trial initiation in 2024 GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade SAN CARLOS, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing tran |
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call TranscriptGrifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript November 2, 2023 Nuria Pascual: Hello, everyone, and welcome to the Grifols Third Quarter 2023 Conference Call. Thank you very much for taking the time to join us today. This is Nuria Pascual, Investor Relations and Sustainability Officer. I’m joined by Thomas Glanzmann, our Executive Chairman and […] |
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTADTrial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease progression up to 38% compared with placebo as measured by the Mini-Mental State Examination scoreVaccine’s unique design offers a new approach to address growing need for effective Alzheimer’s treatments as the prevalence of Alzheimer’s disease is expected to double by the year 2050 in the U.S. alone1 ZARAG |
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum NeurotoxinsModified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studiesSOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the company has been granted an expansion of its contract with the U.S. |